3SBio Forms Investment Partnership with China Medical City

3SBio announced a new investment partnership, called 3SBio Ventures, which it has formed with Taizhou Oriental CMC Limited, the investment arm of Taizhou China Medical City Company. 3SBio hopes to fund projects with the potential of extending its own drug portfolio of biosimilars. 3SBio has committed 200 million RMB ($31.3 million) to the project, and Huan Sheng will add 50 million RMB ($7.8 million). More details.... Stock Symbol: (NSDQ: SSRX)     Share this with colleagues: